ST Pharm
ST Pharm
01
Who we are
02
Our record
03
Newsroom
04
Contact
En
Ko
ST Pharm
Science & Technology
Business Overview
CDMO
Small Molecule
Oligonucleotide
mRNA
CRO
AnaPath Research & Service
R&D
Virtual R&D
Global R&D
About
ST PHARM
Key Members
History
Global Approval
ST Pharm Family
CI
Public
PR (Public Relations)
News room
All
Media Focus
ST PHARM News
IR (Investor Relations)
Stock Information
IR Library
Disclosure Information
IR Materials
Notice
Careers
ESG
Update in progress
Sitemap
Linkedin
Public
IR Materials
PR (Public Relations)
News room
All
Media Focus
ST PHARM News
IR (Investor Relations)
Stock Information
IR Library
Disclosure Information
IR Materials
Notice
IR Materials
Oct 20, 2022
[Analyst Report] Forward path clear
- BUY maintained; 6M TP bumped down 17.2% to W120,000.
- 3Q22 OP to meet expectation, even with sales deferred from 2Q22.
「반출」ST_Pharm_Daishin_Securities_20221020101439.pdf
List
We care about your privacy
This site uses essential cookies necessary for the operation of the service and for maintaining your language preferences. For more information, please review our
Privacy Policy
and
Terms of Service
.
Close
Accept
Decline